The reactivation was significantly earlier, and the predictive cumulative incidence was significantly higher in groups of patients who had HBVDNA > 3 log cps / ml (p=0.005), had HBsAg > 3 log IU / ml (p=0.036) or had G1896A mutation (p=0.001).